Publications
January 30, 2018
A meta-metastasis analysis identifies pan-cancer markers and therapeutic targets
Metastasis is a leading cause of cancer-associated deaths across several cancer types, yet the molecular details of its development have not been fully elucidated. Transcriptomic analysis can provide insight into…
December 9, 2017
Cachexia mechanisms in cancer through the lens of transcriptomics
Introduction: Cachexia is a major clinical complication that affects up to 80% of patients with advanced cancer, and by some estimates is responsible for 20% of cancer deaths [1]. Despite…
December 8, 2017
The international MAQC Society launches to enhance reproducibility of high-throughput technologies
Reproducibility is a fundamental hallmark of good science. The US Food and Drug Administration (FDA)-led Microarray and Sequencing Quality Control (MAQC/SEQC) consortia conducted three projects 1,2,3 to assess the reliability and…
Journal: Nature Biotechnology
December 7, 2017
Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice
Pridopidine is currently under clinical development for Huntington disease (HD), with on-going studies to better characterize its therapeutic benefit and mode of action. Pridopidine was administered either prior to the…
Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice
Pridopidine is currently under clinical development for Huntington disease (HD), with on-going studies to better characterize its therapeutic benefit and mode of action. Pridopidine was administered either prior to the…
Journal: JCI Insight
Proteomic Profiling Reveals Targetable Pathways in MGUS (SLAMF6, TNFRSF8, TIMP1, TRL2) That May Contribute to Disease Progression Blood 2017 130:3805;
Monoclonal gammopathy of undetermined significance (MGUS), is a pre-malignant plasma cell disorder that affects roughly 4% of the population older than 55 and is associated with a 1% per year…
November 23, 2017
Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model.
Copaxone (glatiramer acetate, GA), a structurally and compositionally complex polypeptide nonbiological drug, is an effective treatment for multiple sclerosis, with a well-established favorable safety profile. The short antigenic polypeptide sequences…
Journal: Annals of the New York Academy of Sciences
November 13, 2017
Transcriptomic analysis of the YAC128 HD mouse model shows disease mechanisms are ameliorated by pridopidine.
Huntington Disease (HD) is a neurodegenerative disorder hallmarked by the expression of a mutant form of the huntingtin gene (mHtt). A therapeutic goal for HD treatment involves the restoration of…
May 31, 2017
A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis
Copaxone is an efficacious and safe therapy that has demonstrated clinical benefit for over two decades in patients with relapsing forms of multiple sclerosis (MS). On an individual level, patients…
Journal: Genome Medicine
May 18, 2017
Drug repurposing from the perspective of pharmaceutical companies
Drug repurposing holds the potential to bring medications with known safety profiles to new patient populations. Numerous examples exist for the identification of new indications for existing molecules, most stemming…
Journal: British Journal of Pharmacology
Page 6 of 9
